Disseminated Intravascular Coagulation (DIC) Market Report 2026

The disseminated intravascular coagulation (dic) market size has grown steadily in recent years. It will grow from $0.49 billion in 2025 to $0.51 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to high mortality in critical care, limited early diagnostic tools, sepsis prevalence, trauma-related complications, lack of targeted therapies.

The disseminated intravascular coagulation (dic) market size is expected to see steady growth in the next few years. It will grow to $0.61 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to advanced coagulation diagnostics, improved critical care infrastructure, early intervention protocols, clinical research advancements, awareness programs. Major trends in the forecast period include increased focus on early diagnosis of coagulation disorders, growing use of blood component therapies, expansion of hospital-based critical care treatment, rising awareness of dic in high-risk conditions, adoption of advanced diagnostic monitoring tools.

The rising prevalence of cancer is expected to drive the growth of the disseminated intravascular coagulation (DIC) market in the coming years. Cancer is a condition characterized by the uncontrolled growth and spread of abnormal cells, which can invade and damage healthy tissues. The increase in cancer cases is influenced by factors such as an aging population, lifestyle changes, environmental exposures, infections, and genetic predisposition. Cancer can lead to disseminated intravascular coagulation (DIC) by excessively activating the coagulation cascade through tumor-produced procoagulant substances, resulting in widespread clotting and bleeding. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally. Projections indicate that by 2040, these numbers could rise to 29.9 million new cases and 15.3 million deaths annually. Therefore, the increasing prevalence of cancer is contributing to the growth of the DIC market.

Key companies in the DIC market are focusing on advanced solutions, such as real-time hemostasis monitoring, to improve diagnostic speed, accuracy, and intervention for critically ill patients. Real-time hemostasis monitoring involves the continuous assessment of clot formation and coagulation parameters, providing clinicians with timely insights for better management of coagulopathies. For instance, in February 2024, Roche Diagnostics, a Switzerland-based in vitro diagnostics company, launched three new coagulation assays for Factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) on its cobas t line of automated analyzers. These assays use Roche’s cassette-based reagent system, which standardizes reagent preparation, reduces manual handling, and delivers fast, reliable anti-Xa activity measurement, which is critical for managing DIC patients receiving anticoagulants.

In March 2024, MediLink Therapeutics (Suzhou) Co. Ltd., a China-based biotech company, collaborated with Amgen Inc. to evaluate YL201 for treating thrombotic disorders, including disseminated intravascular coagulation (DIC). This partnership aims to advance therapies for blood clotting disorders, improving treatment effectiveness and patient outcomes. Amgen Inc. is a US-based biopharmaceutical company specializing in the discovery, development, and manufacturing of innovative therapeutics.

Major companies operating in the disseminated intravascular coagulation (dic) market are Nihon Kohden Corporation, Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Abbott Laboratories, Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Siemens Healthineers, Grifols S.A., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc.

North America was the largest region in the disseminated intravascular coagulation (DIC) market in 2025. The regions covered in the disseminated intravascular coagulation (dic) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the disseminated intravascular coagulation (dic) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs impact the disseminated intravascular coagulation market by increasing costs of imported diagnostic reagents, blood testing equipment, and critical care supplies. Hospitals in developed regions are most affected due to advanced diagnostic reliance. These tariffs raise treatment costs. However, they support domestic production of diagnostic consumables and medical devices.

The disseminated intravascular coagulation (dic) market research report is one of a series of new reports that provides disseminated intravascular coagulation (dic) market statistics, including disseminated intravascular coagulation (dic) industry global market size, regional shares, competitors with a disseminated intravascular coagulation (dic) market share, detailed disseminated intravascular coagulation (dic) market segments, market trends and opportunities, and any further data you may need to thrive in the disseminated intravascular coagulation (dic) industry. This disseminated intravascular coagulation (dic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Disseminated intravascular coagulation (DIC) is a complex, life-threatening disorder marked by excessive blood clotting followed by severe bleeding due to the depletion of clotting factors and platelets. It is often triggered by underlying conditions such as sepsis, trauma, malignancies, and obstetric complications.

The primary treatments for disseminated intravascular coagulation (DIC) include medicines, transfusions, surgery, and other therapeutic approaches. Medicines used consist of anticoagulants, blood products, and supportive drugs to manage clotting and bleeding complications associated with DIC. Diagnostic methods include complete blood count with blood smear examination, partial thromboplastin time (PTT), fibrinogen blood test, d-dimer, and additional diagnostic tests. These treatments and diagnostics are administered through various routes, including oral, parenteral, and alternative methods, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies. They are applied across hospitals, specialty clinics, homecare settings, and other end-user environments.

The disseminated intravascular coagulation (DIC) market consists of revenues earned by entities by providing services such as pharmaceutical treatments, anticoagulant therapies, diagnostic services, and critical care interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The disseminated intravascular coagulation (DIC) market also includes sales of diagnostic tools, anticoagulant medications, and blood products such as platelets, fresh frozen plasma, or cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.